September 16, 2025

Three Year Follow-Up of Reduced Dose of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: An Ambispective Cohort Study.

View Full Paper

Ask AI

Bookmark

Authors

EVEmanuele ValerianiVascular Medicine APArianna PannunzioSapienza University of Rome TBTommaso BrogiAzienda Sanitaria Locale Roma 3

Discussion

Member takes

Implication

Ambispective cohort study shows low rates of recurrent VTE and bleeding in patients treated with reduced doses of DOACs, suggesting further cardiovascular risk assessment is needed.

Key Points

Reduced dose of direct oral anticoagulants resulted in just one recurrent vte during follow-up, indicating effective prevention.
The major bleeding rate was low at 2.9%, with two clinically relevant non-major bleeding events also recorded.
Patients primarily received apixaban or rivaroxaban for an average of 2.7 years, with a mean age of 72 years among participants.
Assessment of cardiovascular risk factors is important due to observed arterial events during the follow-up period.

Cite This Study

Valeriani et al. (2025) studied this question.

synapsesocial.com/papers/68c93fee01120bef803bb1b6 https://doi.org/10.3390/diagnostics15172283

View Full Paper

Ask AI

Bookmark

Implication

Ambispective cohort study shows low rates of recurrent VTE and bleeding in patients treated with reduced doses of DOACs, suggesting further cardiovascular risk assessment is needed.

Three Year Follow-Up of Reduced Dose of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: An Ambispective Cohort Study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Three Year Follow-Up of Reduced Dose of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: An Ambispective Cohort Study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider